Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study (2014)
- Authors:
- Autor USP: PEREIRA, JULIANA - FM
- Unidade: FM
- Subjects: LINFOMA (TERAPIA); FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO; SOBREVIDA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Blood
- Volume/Número/Paginação/Ano: v. 124, n. 21, res. 4412, suppl, 2014
- Conference titles: Annual Meeting and Exposition / ASH
-
ABNT
ROBAK, Tadeusz et al. Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study. Blood. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspx. Acesso em: 28 mar. 2024. , 2014 -
APA
Robak, T., Huang, H., Jim, J., Shu, J., Liu, T., Samailova, O. S., et al. (2014). Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study. Blood. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspx -
NLM
Robak T, Huang H, Jim J, Shu J, Liu T, Samailova OS, Pereira J, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov EA, Alexeeva J, Mayer J, Hong X, Maeda Y, Rooney B, van de Velde H, Cavalli F. Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study [Internet]. Blood. 2014 ; 124( 21):[citado 2024 mar. 28 ] Available from: http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspx -
Vancouver
Robak T, Huang H, Jim J, Shu J, Liu T, Samailova OS, Pereira J, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov EA, Alexeeva J, Mayer J, Hong X, Maeda Y, Rooney B, van de Velde H, Cavalli F. Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study [Internet]. Blood. 2014 ; 124( 21):[citado 2024 mar. 28 ] Available from: http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspx - CD4+ lymphocytes in asymptomatic HTLV-1 carriers present cell cycle arrest in GO/G1 phase
- Expression of CysLTR1 and 2 in Maturating Lymphocytes of Hyperplasic Tonsils Compared to Peripheral Cells in Children
- Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome
- Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma
- Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings
- 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era
- Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)
- Follicular lymphoma: refining prognostic models and impact of pod-24 in clinical outcomes
- Factors associated with survival in patients with lymphoma and HIV
- Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas